Scholars Central

OtherPublished 23 Jul 2016

Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial

Authors: Changhoon Yoo, Yoon-Koo Kang

Clinical Investigation

Volume 5 · Issue 7 · Pages 665–675

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Tyrosine kinase inhibitors (TKIs) are the mainstay of the management of advanced gastrointestinal stromal tumors (GISTs). Currently, imatinib, sunitinib and regorafenib are approved treatments for advanced GISTs. However, most standard therapies eventually stop working due to polyclonal evolution of the disease, which results in TKI resistance and overall disease progression. For patients with refractory GISTs after progression on all approved TKIs, resumption of previously effective TKIs may have clinical benefit. However, no randomized trial had been performed to support TKI reuse in patients with advanced GISTs. Recently, a placebo-controlled randomized Phase III trial (RIGHT) found that imatinib resumption significantly prolonged progression-free survival in patients with TKI-refractory GISTs versus placebo. The details of the RIGHT trial and its clinical implications are reviewed here.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Changhoon Yoo”
  • BylineArticles whose byline prints “Yoon-Koo Kang”